Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis

Figure 1 The study flow diagram and the selection process.

Figure 2 Network plots. A: Connections between each study agent included in the randomized controlled trials that assessed glycated hemoglobin; B: Network map for connections between each study agent included in the randomized controlled trials that assessed body weight changes; C: Network graph for level 1 hypoglycemia; D: Network map for minor adverse events; E: Network graph for serious adverse events. ¹One study only; ²two studies.

Figure 3 Network forest plots. A: The network meta-analysis assessing changes in glycated hemoglobin for the drugs vs placebo; B: Body weight changes; C: Risk of level 1 hypoglycemia; drug vs comparator. Apart from liraglutide, other pharmacological agents used for treatment are not associated with statistically significant effects on level 1 hypoglycemia; D: Minor adverse events; E: Serious adverse events. MD: Mean difference; RD: Risk difference.